10.12.2014 13:36:48
|
Supernus Pharma Reports Paragraph IV ANDA Filing For Oxtellar XR - Quick Facts
(RTTNews) - Supernus Pharmaceuticals, Inc. (SUPN), on December 9, 2014, received a Paragraph IV Notice Letter from TWi Pharmaceuticals, Inc., advising Supernus of the filing by TWi of an Abbreviated New Drug Application or ANDA seeking approval for oxcarbazepine extended-release tablets.
Currently, Supernus is reviewing the details of this Notice Letter and plans to vigorously enforce its intellectual property rights relating to Oxtellar XR. The product is now protected by four issued patents that expire no earlier than 2027.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Supernus Pharmaceuticals Incmehr Nachrichten
Keine Nachrichten verfügbar. |
Analysen zu Supernus Pharmaceuticals Incmehr Analysen
Aktien in diesem Artikel
Supernus Pharmaceuticals Inc | 31,60 | -1,25% |
|